1. Introduction {#sec1-cancers-12-00565}
===============

Lymphedema is a dreaded chronic disease affecting more than 5 million people in the United States \[[@B1-cancers-12-00565]\]. Although primary lymphedema can arise from congenital or genetic mutations, the most common cause of lymphedema in Western countries is secondary to lymphatic injury in the course of surgical management of cancer (secondary lymphedema). The rates of lymphedema development following cancer treatment vary widely depending on the length of follow up and the methods used to define or measure lymphedema; however, some studies have reported lifetime rates as high as 50% following axillary lymph node dissection \[[@B2-cancers-12-00565]\]. Further, while breast cancer is the most common cause of secondary lymphedema due to the high prevalence of this malignancy, lymphedema also occurs commonly in patients treated for other solid tumors including melanoma (16%), gynecological cancers (20%), genitourinary tumors (10%), and head/neck malignancies (4%) \[[@B3-cancers-12-00565]\]. Risk factors can include radiation, large radiation field, conventional fractionation radiation, obesity, age, chemotherapy infusion to the affected limb, taxane-based chemotherapy, advanced stage disease, number of lymph nodes removed, and number of positive lymph nodes. \[[@B2-cancers-12-00565],[@B4-cancers-12-00565],[@B5-cancers-12-00565],[@B6-cancers-12-00565],[@B7-cancers-12-00565],[@B8-cancers-12-00565],[@B9-cancers-12-00565],[@B10-cancers-12-00565],[@B11-cancers-12-00565]\] Secondary lymphedema can also result from traumatic injury or infections involving the lymphatic tree. Less frequently, secondary lymphedema can develop in patients due to extreme obesity.

Regardless of etiology, patients with lymphedema experience a variety of symptoms including swelling, pain, decreased range of motion, depression and anxiety \[[@B12-cancers-12-00565],[@B13-cancers-12-00565],[@B14-cancers-12-00565]\]. These symptoms substantially impact quality of life (QOL) and are an important clinical aspect of this disease, resulting in negative changes in functional, social, and psychological domains. Importantly, some patients have profoundly decreased QOL even without significant changes in extremity circumference \[[@B15-cancers-12-00565]\]. These findings suggest, therefore, that assessment of QOL is an important aspect of any study aiming to analyze outcomes following surgical treatment of lymphedema.

There are a number of patient-reported outcome measures (PROMs) available to study QOL in patients with lymphedema. Some of these instruments are lymphedema specific while others are more generic. Lymphedema-specific tools include the lymph quality of life measure for limb lymphedema (LYMQOL) \[[@B16-cancers-12-00565]\], the upper limb lymphedema 27 scale (ULL27) \[[@B17-cancers-12-00565]\], the lymphedema functioning, disability and health questionnaire (Lymph-ICF) \[[@B18-cancers-12-00565]\], and the lymphedema life impact scale (LLIS) \[[@B19-cancers-12-00565]\]. The short form 36 questionnaire (SF-36), is well known and widely used, but not specific to lymphedema \[[@B20-cancers-12-00565]\]. Each tool is distinctive in its examination of QOL in patients with lymphedema and there is currently no consensus on which instrument to use for surgical patients.

While there is no cure for lymphedema, recent surgical treatments aiming to improve lymphatic drainage have gained popularity. These so called physiologic procedures include lymphovenous bypass (LVB), in which lymphatic channels are anastomosed to nearby veins to bypass zones of obstruction, and vascularized lymph node transplant (VLNT), in which lymph nodes are transplanted along with their blood supply to the lymphedematous limb. Interestingly, the majority of studies reporting on these procedures suggest that the best outcomes are obtained in patients with early stage disease and limited limb swelling \[[@B21-cancers-12-00565]\]. This makes intuitive sense since it is widely accepted that early intervention for most diseases is associated with better outcomes. However, this fact also presents a clinical challenge in measuring outcomes since patients with early stage disease tend to have relatively small increases in limb volume excess. Thus, objective outcomes focusing on improvements in limb swelling may not fully capture the positive benefits of surgical intervention as reflected by changes in QOL. This problem is accentuated by the fact that there is no correlation between limb volume excess and impairments in QOL. As a result, these issues underline the importance of PROMs in the assessment of outcomes following lymphatic reconstruction. Nevertheless, to our knowledge, there has been no systematic review focusing on QOL after surgical treatment for lymphedema. Therefore, the purpose of this study was to perform a systematic review of subjective outcomes following LVB or VLNT and to analyze trends in PROM use in the literature.

2. Methods {#sec2-cancers-12-00565}
==========

A systematic review of contemporary peer-reviewed literature was performed to evaluate the QOL outcomes in the physiologic surgical treatment of lymphedema. On March 7, 2019, four databases were searched: Medline (PubMed), Embase.com, the Cochrane Library (Wiley), and Health and Psychosocial Instruments (Ovid). In all databases but Health and Psychosocial Instruments, the search had two main categories, combined using the AND operator: (1) lymphedema and (2) lymphovenous anastomosis or lymph node transplant. The search in Health and Psychosocial Instruments looked only for lymphedema-related instruments. In PubMed and Embase, we used the *Cochrane Handbook* filter for excluding animal-only studies \[[@B22-cancers-12-00565]\]. We saved all references to the citation management software EndNote and removed duplicates following the Bramer Method \[[@B23-cancers-12-00565]\].

Two reviewers independently reviewed 850 abstracts after removal of duplicates and 105 full texts. Clinical studies describing QOL outcomes after surgical treatment of extremity lymphedema with either LVB or VLNT, with a minimum sample size of four patients and written in English were included in our study. Non-referenced articles, case reports, review articles and non-human articles were excluded. A total of 32 studies matched inclusion criteria ([Figure 1](#cancers-12-00565-f001){ref-type="fig"}).

Data extracted from each study included number of patients, etiology of lymphedema, stage of lymphedema, upper versus lower extremity, type of surgical procedure, other therapies used, donor site for VLNT, and follow up time/tool used for QOL assessment. Descriptive and summary statistics were used to evaluate the articles. Pearson correlation coefficient was used to assess the use of validated and ad-hoc survey tools over time.

3. Results {#sec3-cancers-12-00565}
==========

QOL was reported as an outcome measure after physiologic surgical treatment for lymphedema in 32 articles involving 954 patients. Weighted average follow-up time was 9.2 months. LVB was the primary surgical treatment in 18 studies, and VLNT in 14 studies. All studies showed an improvement in QOL (range 50--100%). Individual patient data was reported in 18 studies, totaling 717 patients. Between 50% and 100% of patients showed improvement. One-half of the studies we reviewed (n = 16) used a QOL tool without evidence of a development or psychometric validation process (i.e., ad-hoc instrument). PROMs were used in the remainder of studies and included LYMQOL (n = 12, 38%), the ULL27 (n = 1, 3%), the Lymph-ICF (n = 1, 3%), the LLIS (n = 1, 3%) and the SF-36 (n = 1, 3%; ([Table 1](#cancers-12-00565-t001){ref-type="table"}). Over time, the proportion of studies utilizing validated tools increased (r = 0.5), while the proportion of studies using an ad-hoc questionnaire decreased (r = -0.5) ([Figure 2](#cancers-12-00565-f002){ref-type="fig"}).

3.1. Patient-Reported Outcomes after LVB {#sec3dot1-cancers-12-00565}
----------------------------------------

### 3.1.1. Ad-Hoc Patient Questionnaires {#sec3dot1dot1-cancers-12-00565}

Twelve studies analyzing outcomes following LVB assessed QOL outcomes with ad-hoc questionnaires ([Table 2](#cancers-12-00565-t002){ref-type="table"}). O'Brien et al. analyzed outcomes of 46 upper extremity and 6 lower extremity LVB procedures \[[@B24-cancers-12-00565]\]. At an average follow up of 4.2 months, 38 of 52 (78%) patients experienced subjective improvement including a decrease in size, better fitting clothes, softer skin and decreased frequency of cellulitis. A few patients, 3 of 52 (6%) felt they were worse. Most patients, 83%, were able to discontinue conservative measures post-operatively. Demirtas et al. performed LVB in the lower extremities of 42 patients \[[@B25-cancers-12-00565]\]. At an average follow up of 11.8 months, 40 of 42 (95%) patients were satisfied with the result and felt improved in terms of decreased size, decreased weight of the limb, softer, better texture of skin, easier fitting of clothes and decreased infections. Auba et al. performed LVB of either the upper or lower extremity in 10 patients \[[@B26-cancers-12-00565]\]. Qualitative evaluation was done by recording subjective symptoms that patients reported during follow up. At 18 months follow up, 9 of 10 (90%) patients reported noticeable improvements in their symptoms (skin induration, sensation of swelling, worsening in the summer, requirement of garments, difficulty wearing clothing, numbness, erythema and mobility). Ayestaray et al. studied 20 patients with lymphedema of the upper extremity \[[@B27-cancers-12-00565]\]. LVB was performed and at 6 months post-operative, 19 of 20 (95%) patients had improvements in their soft tissues. They also noted that 18 of 20 (90%) patients moved to a better QOL, although there is no mention as to how QOL was measured. Chang et al. reported that 19 of 20 patients (95%) that underwent LVB of the upper extremity had improvements in the symptoms of lymphedema (arm was lighter, softer and less painful) shortly following surgery \[[@B28-cancers-12-00565]\]. However, at 12 months follow up, these findings were sustained in only 16 of 20 (80%). In another study, Chang et al. reported on outcomes in 100 consecutive patients treated with LVB for either upper or lower extremity lymphedema \[[@B29-cancers-12-00565]\]. Average follow up for upper extremity patients was 30.4 months and 96% of patients reported their arm felt lighter, softer, and less painful. Average follow up for lower extremity patients was 18.2 months and 57% noted symptomatic improvement. Poumellec et al. reported that at 12.7 months after LVB for upper extremity lymphedema, substantial functional improvement was noted in 17 of 31 (55%) patients, and moderate improvement in 9 (29%) patients \[[@B30-cancers-12-00565]\].

Three studies described creation of ad-hoc study specific tools. Chung et al. created their own questionnaire in a retrospective study of 18 patients undergoing LVB for either upper or lower extremity lymphedema \[[@B31-cancers-12-00565]\]. The questionnaire had eight questions, scored from 0 to 5, with higher scores being better than lower scores. Three questions were related to volume, two questions were related to softness, and three questions were related to overall satisfaction. The questionnaire was administered at 6 months post-operatively. Scores were compared between patients with upper versus lower extremity lymphedema and between Campisi stage 2 and 3/4. Generally, patients with stage 2 upper extremity lymphedema had the highest average scores. Patients with stage 3/4 lower extremity lymphedema had the lowest average scores. Mihara et al. also created a study specific tool evaluating sensations of pain, strange feelings, and tension \[[@B32-cancers-12-00565]\]. In 6 patients with secondary lower extremity lymphedema, all patients (100%) noted improvements at 6 months post-operatively. In another study by Mihara *et al,* a study specific tool was used to inquire about limb softness, pain, and severity of lower extremity lymphedema \[[@B33-cancers-12-00565]\]. At 18.3 months, 67 of 84 (80%) patients had improvement and 4 felt worse.

Two studies reported outcomes of LVB, with or without VLNT, using ad-hoc study specific tools. Chen et al. used a study specific tool evaluating severity of lymphedema symptoms and degree of disability and reported that these symptoms are reversed by LVB in 19 patients and VLNT from the groin (1 patient) or supraclavicular region (2 patients) at 12 months follow up \[[@B34-cancers-12-00565]\]. Significant improvement in scores was noted from pre-operative to post-operative (*p* \< 0.01). Masia et al. used a study specific tool evaluating episodes of lymphangitis, pain, swelling, heaviness, loss of sensitivity, loss of mobility, anxiety/depression, impact on daily activities, and the use of conservative therapies \[[@B35-cancers-12-00565]\]. Two hundred patients with upper extremity lymphedema were included in the study having the following procedures: LVB (81 patients), VLNT from the groin (7 patients), DIEP/SIEA with groin lymph nodes (16 patients), LVB + VLNT (44 patients), liposuction (52 patients). Of all patients, 192 (96%) reported subjective improvement, 8 patients reported no change.

### 3.1.2. LYMQOL {#sec3dot1dot2-cancers-12-00565}

Four papers reported on LVB outcomes using the LYMQOL ([Table 3](#cancers-12-00565-t003){ref-type="table"}). Winters *et al*, in two separate studies---one with 29 patients and 12 month follow up and another with 12 patients and 6 month follow up---compared pre-operative to post-operative LYMQOL surveys in patients with upper extremity lymphedema \[[@B36-cancers-12-00565],[@B37-cancers-12-00565]\]. In both studies, all subscales and the overall quality of life improved significantly (*p* \< 0.01). Gentileschi et al. reported a significant increase in the average overall score using the LYMQOL at 6 months after LVB for treatment of upper extremity lymphedema in 16 patients (*p* \< 0.001) \[[@B38-cancers-12-00565]\]. Salgarello et al. used the LYMQOL to evaluate outcomes of LVB for treatments of either upper extremity (n = 44) or lower extremity (n = 26) lymphedema at an average of 8.5 months \[[@B39-cancers-12-00565]\]. Significant improvements were noted in the overall score as well as all subscales (*p* \< 0.01).

### 3.1.3. Lymph-ICF {#sec3dot1dot3-cancers-12-00565}

Cornelissen et al. performed LVB on 20 patients with upper extremity lymphedema and the Lymph-ICF was used to evaluate outcomes at 12 months \[[@B40-cancers-12-00565]\]. Significant improvements in all subscales and total score was seen (*p* \< 0.05). ([Table 3](#cancers-12-00565-t003){ref-type="table"}).

### 3.1.4. SF-36 {#sec3dot1dot4-cancers-12-00565}

Damstra et al. performed LVB on 10 patients with upper extremity lymphedema \[[@B41-cancers-12-00565]\]. SF-36 was completed pre-operatively and at 6 months post-operatively. At a follow up of 6 months, 5 of 10 patients (50%) felt less disabled on the SF-36 questionnaire. ([Table 3](#cancers-12-00565-t003){ref-type="table"}).

3.2. Patient-Reported Outcomes after VLNT {#sec3dot2-cancers-12-00565}
-----------------------------------------

### 3.2.1. Ad-Hoc Patient Questionnaires {#sec3dot2dot1-cancers-12-00565}

Four studies analyzing VLNT assessed QOL outcomes with no specific validated tool ([Table 4](#cancers-12-00565-t004){ref-type="table"}). Gharb et al. evaluated 21 patients with upper extremity lymphedema who underwent VLNT using groin lymph nodes \[[@B42-cancers-12-00565]\]. Ten patients also had liposuction. At an average of 43.1 months, average scores on a visual analog scale improved, although not significantly. Nguyen et al. report their series of 42 patients who had vascularized omentum flaps for treatment of either upper or lower extremity lymphedema, with 55% of patients also having LVB \[[@B43-cancers-12-00565]\]. Average follow up was 14 months and they report subjective improvements in swelling, fatigue, heaviness, tightness, stiffness, sleep loss, aching, and skin quality in 35 of 42 patients (83%). There is no mention as to how data regarding symptoms was obtained and when.

Coriddi et al. analyzed results of the vascularized jejunal mesenteric lymph node transplant in 15 patients with either upper or lower extremity lymphedema \[[@B44-cancers-12-00565]\]. One patient suffered a flap loss. At a mean follow up of 9.1 months, 12 of 14 patients had subjective improvement (85.7%). Further details are not mentioned. Dionyssiou et al. published their results of a randomized control trial comparing VLNT from the groin to the upper extremity compared to conservative treatment over a follow up period of 12 months \[[@B45-cancers-12-00565]\]. A visual analogue scaling system (1--10) was used to assess pain, heaviness and functional disturbances. All 18 patients (100%) who received VLNT reported significant improvement at 12 months from pre-operative measurements in the pain, heaviness and function scales (*p* \< 0.001). Additionally, when comparing groups, the scores for pain, heaviness and function were significantly better at 12 months in the VLNT group compared to the conservative management group (*p* \< 0.001).

### 3.2.2. LYMQOL {#sec3dot2dot2-cancers-12-00565}

Eight papers reporting on VLNT utilized the LYMQOL in outcome analysis ([Table 5](#cancers-12-00565-t005){ref-type="table"}). Ciudad et al. report their results of transplant of the right gastroepiploic lymph node flap to either the groin (5 patients) or axilla (5 patients) \[[@B46-cancers-12-00565]\]. When comparing average pre-operative scores with average one year post-operative scores, significant improvements in all subscales as well as the overall score were noted (p\<0.01). Patel et al. examined 25 patients, 15 upper extremity and 10 lower extremity, with either primary or secondary lymphedema \[[@B47-cancers-12-00565]\]. VLNT was done using either a groin or submental lymph node flap. Average LYMQOL scores were recorded pre-operatively and at 1, 3, 6, 9 and 12 months post-operation. In both the upper and lower extremity patients, all subscales were improved and reached statistical significance by 9 months post-operation (range p\<0.01 to p\<0.05). Asuncion et al. use LYMQOL pre-operatively and at 12 months post-operatively to evaluate outcomes of 15 patients who underwent submental VLNT to either upper or lower extremity \[[@B48-cancers-12-00565]\]. At 12 months, there was a significant improvement in the average score for all subscales and overall QOL (range *p* \< 0.02 -- p \< 0.04). Ciudad et al. reported their results following double gastroepiploic VLNT combined with soft tissue de-bulking \[[@B49-cancers-12-00565]\]. At 12 months post-operation, significant improvements in the average scores in all subscales as well as the overall score were noted for both the upper and lower extremity groups (*p* \< 0.01). Visconti et al. reported the technique and outcomes of compartmental dual lymph node transplant from the right supraclavicular area to the lower extremity in 10 patients with lymphedema \[[@B50-cancers-12-00565]\]. LYMQOL surveys were completed pre-operatively and at 6 and 12 months post-operatively. All patients reported improvement in QOL. Average scores for all subscales and overall score improved from the pre-operative survey to the 6 month post-operative survey, and again from the 6 month survey to 12 month survey. Maruccia performed VLNT using groin or gastroepiploic lymph nodes to the upper extremity in 39 patients \[[@B51-cancers-12-00565]\]. In 18 of the 39, scar release and fat grafting were performed as well. At 12 months follow up, LYMQOL average scores for both groups were significantly improved (*p* \< 0.001).

Gratzon et al. used the LYMQOL and also two paper specific scales (pain and heaviness) to evaluate outcomes in 50 patients \[[@B52-cancers-12-00565]\]. The pain scale and heaviness scales were both based on a standard 1--10 ratings. Evaluation was done pre-operatively and at 1, 3, 6, 9 and 12 months post-operatively. Twenty-four patients completed follow up at one year and had either a groin, lateral thoracic or supraclavicular VLNT to the upper extremity for secondary lymphedema. In terms of LYMQOL outcomes, all subscales and the overall score reached significant improvement by 3 months post-operation (*p* \< 0.01). Using the paper specific pain and heaviness scales, pain reached significant (*p* \< 0.01) improvement at 1 month post-operation and heaviness reached significant (*p* \< 0.01) improvement at 1 month post-operation.

Cheng et al. evaluated 19 patients using the LYMQOL---15 who underwent submental VLNT and 4 who underwent LVB \[[@B53-cancers-12-00565]\]. At 12 months follow up, average scores for all domains and the overall QOL score improved significantly in the VLNT groups (*p* \< 0.05). The LVB group showed improvement in the overall score, and the function, appearance, symptoms and mood domains (*p* = 0.07, 0.1, 0.1, 0.07, 0.07 respectively).

### 3.2.3. ULL27 {#sec3dot2dot3-cancers-12-00565}

One study utilized the ULL27 in outcome analysis ([Table 5](#cancers-12-00565-t005){ref-type="table"}). De Brucker et al. performed VLNT to the axilla of the affected arm using the groin as the flap donor site \[[@B54-cancers-12-00565]\]. At an average follow up time of 29 months (range 8--64 months), there was a statistically significant improvement in the mean overall score of the ULL27 (*p* \< 0.001). Average post-operative scores for each of the ULL27 domains (physical, psychological, social) also improved. Looking at individual data, 21 of 25 patients had improved scores, 3 patients had no change, and 1 patient was worse.

### 3.2.4. LLIS {#sec3dot2dot4-cancers-12-00565}

The LLIS was used to assess outcomes in 14 patients who underwent VLNT using a muscle-sparing latissimus dorsi flap \[[@B55-cancers-12-00565]\]. Inbal et al. report at a mean follow up of 6.7 months (range 3--12 months), 10 patients (91%) reported symptomatic improvement including softer, lighter and less painful extremities than prior to surgery. Average LLIS scores improved over time. However, of 14 patients, only 9 patients presented for evaluation at 3 months follow up and only 5 patients at 12 months. ([Table 5](#cancers-12-00565-t005){ref-type="table"}).

4. Discussion {#sec4-cancers-12-00565}
=============

QOL improvement was reported in all papers evaluated in this systematic review examining outcomes after LVB and/or VLNT in patients with either upper or lower extremity secondary or primary lymphedema. QOL is an important outcome measure in lymphedema surgery. Previous studies have shown that although volume changes may not be evident, patients with lymphedema can have significant QOL impairments. Additionally, the severity of volume change does not necessarily correlate with subjective outcomes, as patients with relatively minor volume changes can experience very significant psychosocial and/or physical challenges \[[@B15-cancers-12-00565],[@B56-cancers-12-00565]\]. Hormes et al. found in his study of 295 women, arm swelling and lymphedema severity were less correlated with QOL than total number of arm symptoms and specific individual symptoms \[[@B15-cancers-12-00565]\]. A study of breast cancer patients treated with neoadjuvant chemotherapy and axillary lymph node dissections showed slight agreement, with the kappa coefficient ranging from 0.05 to 0.09, when examining lymphedema symptoms of arm swelling and heaviness compared to volume or circumference measurements \[[@B57-cancers-12-00565]\]. At our institution, we have seen some patients with minimal or low excess volumes measurements report a high degree of impairment in QOL \[[@B56-cancers-12-00565]\]. Despite these facts, the vast majority of studies reporting outcomes following surgical treatment of lymphedema have focused primarily on objective changes in limb volume or fluid content while a relative minority have also reported on PROMs. To our knowledge, this is the first systematic review of QOL changes following surgical physiologic lymphatic reconstruction.

Our systematic review found that QOL improvements can occur relatively early following surgery. The average weighted follow up for all studies was 9 months. Two papers that evaluated QOL using the LYMQOL found significant improvements in as little as 1 month post-operatively. Gratzon et al. reporting outcomes following VLNT to the upper extremity, found that the subscale of symptoms on the LYMQOL is significantly improved as early as 1 month after surgery. Additionally, at one month post-operatively, pain and heaviness improved significantly when measured on their paper specific scale \[[@B52-cancers-12-00565]\]. Patel et al. reported significant improvement on the LYMQOL function subscale 1 month following VLNT in 15 patients with upper extremity lymphedema \[[@B47-cancers-12-00565]\]. Studies with longer term follow up are needed to ensure these findings persist and are not simply related to post-operative behavior modifications (e.g., elevation, changes in activity, or improvements in compliance with compression). For example, Chang et al. used a non-validated survey tool and reported initial improvement after LVB in 95% of patients \[[@B28-cancers-12-00565]\]. However, improvement was only sustained in 80% at one year after surgery.

In the eighteen papers that report individual patient data, we noted that the majority of patients (50%--100%) improve following LVB or VLNT. In four studies, all patients reported improvement. The remaining studies have a small percentage of patients who either experienced no change or were worse. This is an important finding to consider. While most studies focus on the improvements after physiologic surgical treatment of lymphedema, negative results are also important and have a direct impact on patient counseling. However, due to the progressive nature of the disease, determining the etiology of worsening QOL post-operatively is difficult. While it is possible that surgery could damage functional lymphatics leading to increased lymphedema and decreased QOL, it is also possible that these surgical interventions failed to improve lymphatic drainage and the disease, as expected, worsened over time.

Our study shows that there is little consensus in the literature on the use of PROMs to study outcomes following lymphatic surgery. Indeed, many studies reviewed in our paper (half of the papers that met inclusion criteria), failed to use validated instruments and relied on questionnaires developed in an ad hoc manner. Validated PROMs are developed using rigorous qualitative and quantitative psychometric methods to ensure that reliable, accurate, interpretable data is obtained and that the measurement tool is well targeted to the population being studied \[[@B58-cancers-12-00565]\]. Therefore, to examine changes in QOL specific to lymphedema, the use of a validated PROM is critical to surgical outcomes research and advancement of this field. In this study, we noted that the proportion of published studies using a validated PROM has steadily increased over time. With the exception of one prior study, physiologic surgical treatment for lymphedema research began including QOL as an outcome measure in 2009. The earlier studies more often used non-validated tools or generic tools like the SF-36, even though the ULL27 was validated in 2002. The LYMQOL was validated in 2010 and has become the most widely applied tool since. While the use of validated tools is becoming more common, some recent studies continue to use non-validated measures. Considering the number of validated tools available and the ease of accessibility, the use of a validated tool in lymphedema research should be standard.

Among the 16 studies with validated PROMs, a variety of measures were used, including the LYMQOL (n = 12), ULL27 (n = 1), LLIS (n = 1), Lymph-ICF (n = 1), and SF-36 (n = 1). This heterogeneity makes comparison of outcomes across studies difficult. Consensus among lymphedema researchers regarding which QOL(s) to use is therefore important and necessary.

Which tool should be recommended? While the SF-36 is well known and widely used, a lymphedema-specific PROM which captures the particular psychologic, social and physical factors contributing to quality of life changes caused by lymphedema is likely more useful. When examining the efficacy of surgical procedures aimed at treating lymphedema, a lymphedema-specific evaluation tool ensures QOL changes are specific to lymphedema, compared to the use of a generic tool such as the SF-36 which would evaluate a general health status. The LYMQOL, ULL27, LLIS, and Lymph-ICF are all validated and comprehensive, lymphedema-specific questionnaires. In 2013, Pusic et al. evaluated lymphedema-specific PROMs and found the ULL27 had strong psychometric properties \[[@B59-cancers-12-00565]\]. Since that time, however, the clinical characteristics of patients eligible for lymphedema surgery has shifted, with patients with less severe disease potentially benefitting. Given this, it is unclear whether the ULL27 continues to be well targeted across the entire spectrum of the patients. In terms of PROM contents, all evaluated physical and psychosocial issues that can affect patients with lymphedema. The LYMQOL also asks about worry, irritability, feeling of being tense, and depression that can plague those suffering from lymphedema. Similarly, the ULL27 asks about feeling sad, discouraged, distressed, or angry. The LLIS inquiries about feelings of depression, frustration or anger and the Lymph-ICF asks about feeling sad, frustrated and insecure about the future due to lymphedema but neither not touch on feelings of anxiety as directly. The LYMQOL, LLIS and Lymph-ICF are available for both upper and lower extremity evaluation, while the ULL27 is dedicated to upper extremity only.

An important limitation of our review is that it was outside the scope of our study to critically appraise the development and validation process of the lymphedema-specific PROMs identified in our search. Future research is needed that employs the COSMIN (COnsensus-based Standards for the selection of health Measurement Instruments) methodology, now used in an increasing number of reviews of PROMs, to examine the development process and psychometric properties of each PROM. The COSMIN methodology provides guidance and criteria for judging a range of psychometric properties, including content validity, structural validity, internal consistency, cross-cultural validity, reliability, measurement error, criterion validity, construct validity and responsiveness. Research that appraises PROMs using the COSMIN approach, could help to answer the question on which is the best PROM to use in future research \[[@B60-cancers-12-00565]\].

This study has additional limitations. Summarization of outcomes specific to primary versus secondary lymphedema, upper extremity versus lower extremity is difficult as results regarding quality of life are often reported grouped together, including all patients in the study. Similarly, assessment of VLNT versus LVB is difficult, as some authors perform both treatments simultaneously or include a physiologic surgery with a reductive surgery. Additionally, this review is specific to physiologic procedures to treat lymphedema. Other survey tools may be used more predominantly in other fields, such a lymphedema therapy. Also, while we do see an improvement in quality of life in this study, no studies were blinded and therefore there may be a component of placebo effect. Further, more rigorous studies using a validated PROMs, preferably one common tool across all lymphedema research, with longer follow up, are needed to confirm the improvement in QOL in patients undergoing physiologic procedures for treatment of lymphedema.

5. Conclusions {#sec5-cancers-12-00565}
==============

Patients who suffer from lymphedema and undergo treatment with physiologic procedures such as LVB or VLNT have significant improvements in QOL. The use of lymphedema-specific PROMs has increased progressively over the past decade. This is important since QOL changes related to lymphedema may not correlate with limb volumes and because surgical treatments have the highest efficacy in patient with early stage (i.e., low volume) disease. Additional studies are needed using validated tools to confirm QOL improvements after LVB or VLNT and to guide patient selection, shared surgical decision making and future innovation.
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cancers-12-00565-t001_Table 1

###### 

Validated quality of life tools.

  Validated Tool   Lymphedema Specific   Categories                                                                                                                                                                                                                      Number of Questions     Lookback Period      Upper/Lower Extremity   Score Calculation
  ---------------- --------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------- -------------------- ----------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  LYMQOL           Yes                   Four subscales: pain, mood, function and appearance, and an additional question on overall quality of life                                                                                                                      24 (upper) 25 (lower)   1 week (mood only)   Both                    A 4-point Likert scale with additional questions that are free response. Each dimension is scored, resulting in one number for each section. The overall quality of life score is on a 1-10 scale.
  ULL27            Yes                   Three subscales: physical, psychological, and social                                                                                                                                                                            27                      4 weeks              Upper                   A 5-point Likert scale. Each dimension is scored, resulting in one number for each section.
  Lymph-ICF        Yes                   Five subscales: physical function, mental function, household activities, mobility activities, and life and social activities                                                                                                   29                      2 weeks              Both                    An 11-point Likert scale. Each dimension is scored, resulting in one number for each section.
  LLIS             Yes                   Three subscales: physical, psychosocial, functional, and an additional question on infection occurrence                                                                                                                         18                      1 week               Both                    A 5-point Likert scale. Each dimension is scored, resulting in one number for each section.
  SF-36            No                    Eight subscales: physical functioning, role limitations as a result of physical problems, bodily pain, general health perception, vitality, social functioning, role limitations due to emotional problems, and mental health   36                      4 weeks              Both                    The domains are combined to create a physical component score and a mental component score.
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###### 

Quality of life (QOL) in lymphovenous bypass (LVB) using ad-hoc tools.

  Study              Year Published   Number of Patients   Stage                                                                            Lymphedema Site    Primary vs. Secondary          Surgical Procedure                                                                           Baseline QOL Measure Administered Pre-Operatively?   Average Follow-Up Time       QOL Measure   Percent of Patients with Subjective Improvement
  ------------------ ---------------- -------------------- -------------------------------------------------------------------------------- ------------------ ------------------------------ -------------------------------------------------------------------------------------------- ---------------------------------------------------- ---------------------------- ------------- -------------------------------------------------
  O'Brien            1990             52                   Not mentioned                                                                    UE (46), LE (6)    Secondary                      LVB                                                                                          Not mentioned                                        4.2 mo                       Ad-hoc tool   73%
  Demirtas et al.    2009             42                   Campisi stage II (12), III (17), IV (13)                                         LE                 Secondary (34), Primary (8)    LVB                                                                                          Not mentioned                                        11.8 mo                      Ad-hoc tool   95%
  Chang              2010             20                   Capisi stage II (10), III (10)                                                   UE (20)            Secondary                      LVB                                                                                          Yes                                                  12 mo                        Ad-hoc tool   80%
  Auba et al.        2012             10                   Campisi stage II (2), III (8)                                                    LE (4), UE (6)     Secondary (9), Primary (1)     LVB                                                                                          No                                                   18 mo                        Ad-hoc tool   90%
  Mihara et al.      2012             6                    ISL 0 (3), 1 (3)                                                                 LE                 Secondary                      LVB                                                                                          Yes                                                  6 mo                         Ad-hoc tool   100%
  Ayestaray et al.   2013             20                   Campisi stage II (9), III (7), IV (3), V (1)                                     UE                 Not mentioned                  LVB                                                                                          Yes                                                  6 mo                         Ad-hoc tool   95%
  Chang et al.       2013             100                  ICG classification stage 1 or 2 (16), 3 or 4 (14). Not all patients classified   UE (89), LE (11)   Secondary                      LVB                                                                                          Not mentioned                                        30.4 mo (UE), 18.2 mo (LE)   Ad-hoc tool   96% (UE), 57% (LE)
  Mihara et al.      2016             84                   ISL 1 (30), 2a (39), 2b (36), 3 (23)                                             LE                 Primary (15), Secondary (69)   LVB                                                                                          Yes                                                  18.3 mo                      Ad-hoc tool   80%
  Chen et al.        2016             21                   Campisi I and II (9), III (4), IV (8)                                            UE (13), LE (8)    Primary (4), Secondary (17)    LVB (18) or VLNT (3)                                                                         Yes                                                  12 mo                        Ad-hoc tool   100%
  Masia et al.       2016             200                  Not mentioned                                                                    UE (200)           Secondary (200)                LVB (81), VLNT (7), DIEP/SIEA with groin lymph nodes (16), LVB+VLNT (44), liposuction (52)   Yes                                                  12 mo                        Ad-hoc tool   96%
  Poumellec et al.   2017             31                   Campisi stage 2 (18), 3 (10), 4 (3)                                              UE                 Secondary                      LVB                                                                                          Yes                                                  12.7 mo                      Ad-hoc tool   84%
  Chung et al.       2019             18                   Campisi stage II (7), III or IV (11)                                             UE (8), LE (10)    Secondary                      LVB                                                                                          No                                                   6 mo                         Ad-hoc tool   Individual patient data not reported

ISL, international society of lymphology; UE, upper extremity; LE, lower extremity; LVB, lymphovenous bypass; VLNT, vascularized lymph node transplant; DIEP, deep inferior epigastric perforator flap; SIEA, superficial inferior epigastric perforator flap; mo, months.

cancers-12-00565-t003_Table 3

###### 

QOL in LVB using validated tools.

  Study                Year Published   Number of Patients   Stage                    Lymphedema Site    Primary vs. Secondary         Surgical Procedure   Baseline QOL Measure Administered Pre-Operatively?   Average Follow-Up Time Regarding Subjective Assessment   QoL Measure   Percent of Patients with Subjective Improvement
  -------------------- ---------------- -------------------- ------------------------ ------------------ ----------------------------- -------------------- ---------------------------------------------------- -------------------------------------------------------- ------------- -------------------------------------------------
  Damstra et al.       2009             10                   Campisi stage III (10)   UE                 Secondary                     LVB                  Yes                                                  6 mo                                                     SF-36         50%
  Cornelissen et al.   2017             20                   ISL 1 (1), 2a (19)       UE                 Secondary                     LVB                  Yes                                                  12 mo                                                    Lymph-ICF     Individual patient data not reported
  Gentileschi et al.   2017             16                   ISL 2a (7), 2b (9)       UE                 Secondary                     LVB                  Yes                                                  6 mo                                                     LYMQOL        Individual patient data not reported
  Winters et al.       2017             29                   Campisi stages 1b--2a    UE                 Secondary                     LVB                  Yes                                                  12 mo                                                    LYMQOL        Individual patient data not reported
  Salgarello et al.    2018             74                   Not mentioned            UE (44), LE (26)   Primary (5), Secondary (55)   LVB                  Yes                                                  8.5 mo                                                   LYMQOL        Individual patient data not reported
  Winters et al.       2019             12                   Campisi stages 1--2a     UE                 Secondary                     LVB                  Yes                                                  6 mo                                                     LYMQOL        Individual patient data not reported

ISL, international society of lymphology; UE, upper extremity; LE, lower extremity; LVB, lymphovenous bypass; mo, months; SF-36, short form 36 questionnaire; Lymph-ICF, lymphedema functioning, disability and health questionnaire; LYMQOL, lymph quality of life measure for limb lymphedema.
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###### 

QOL in VLNT using ad-hoc tools.

  Study               Year Published   Number of Patients   Stage                                      Lymphedema Site    Primary vs. Secondary                            Surgical Procedure           Donor Site (Lymph Node Transplant)   Baseline QOL Measure Administered Pre-Operatively?   Average Follow-Up Time Regarding Subjective Assessment   QOL Measure   Percent of Patients with Subjective Improvement
  ------------------- ---------------- -------------------- ------------------------------------------ ------------------ ------------------------------------------------ ---------------------------- ------------------------------------ ---------------------------------------------------- -------------------------------------------------------- ------------- -------------------------------------------------
  Gharb et al.        2011             21                   Not mentioned                              UE                 Secondary                                        VLNT (10 also liposuction)   Groin                                Yes                                                  43.1 mo                                                  Ad-hoc tool   Individual patient data not reported
  Dionyssiou et al.   2016             18                   ISL stage II (18)                          UE                 Secondary                                        VLNT                         Groin                                Yes                                                  12 mo                                                    Ad-hoc tool   100%
  Coriddi et al.      2017             15                   Not mentioned                              UE (8), LE (7)     Secondary                                        VLNT                         Jejunal Mesentery                    Not mentioned                                        9.1 mo                                                   Ad-hoc tool   86%
  Nguyen et al.       2017             42                   Modified ICG stage 3 (9), 4 (18), 5 (15)   UE (19), LE (24)   Secondary (37), Primary (2), not mentioned (3)   VLNT (55% also having LVA)   Omentum                              Not mentioned                                        14 mo                                                    Ad-hoc tool   83%

ISL, international society of lymphology; UE, upper extremity; LE, lower extremity; LVB, lymphovenous bypass; VLNT, vascularized lymph node transplant; mo, months.
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###### 

QOL in VLNT using validated tools.

  Study               Year Published   Number of Patients   Stage                                                                                  Lymphedema Site                   Primary vs. Secondary         Surgical Procedure                                           Donor Site (Lymph Node Transplant)                 Baseline QOL Measure Administered Pre-Operatively?   Average Follow-Up Time Regarding Subjective Assessment   QoL Measure                                                                          Percent of Patients with Subjective Improvement
  ------------------- ---------------- -------------------- -------------------------------------------------------------------------------------- --------------------------------- ----------------------------- ------------------------------------------------------------ -------------------------------------------------- ---------------------------------------------------- -------------------------------------------------------- ------------------------------------------------------------------------------------ ----------------------------------------------------
  Patel et al.        2015             25                   Scale specific to this paper, I (1), II (6), III (13), IV (5)                          UE (15), LE (10)                  Secondary (23), Primary (2)   VLNT                                                         Groin or submental                                 Yes                                                  12 mo                                                    LYMQOL                                                                               Individual patient data not reported
  De Brucker et al.   2016             25                   Stage 1 and 2 (classification system and number of patients per stage not mentioned)   UE                                Secondary                     VLNT                                                         Groin                                              No                                                   29 mo                                                    ULL27                                                                                84%
  Ciudad et al.       2017             10                   ISL stage II (2), ISL stage III (8)                                                    UE (5), LE (5)                    Secondary                     VLNT                                                         Right gastroepiploic lymph node flap               Yes                                                  14.7 mo                                                  LYMQOL                                                                               Individual patient data not reported
  Gratzon et al.      2017             24                   Not mentioned                                                                          UE                                Secondary                     VLNT                                                         Groin, lateral thoracic, supraclavicular           Yes                                                  12 mo                                                    LYMQOL and study specific pain scale and heaviness scale with standard 1-10 rating   Individual patient data not reported
  Inbal et al.        2017             11                   ISL stage 1 (4), 2 (7)                                                                 UE (8), LE (3)                    Secondary                     VLNT (64% also having LVB)                                   Thoracic on muscle sparing latissimus dorsi flap   Yes                                                  6.7 mo                                                   LLIS                                                                                 91%
  Cheng et al.        2018             19                   Not mentioned                                                                          LE (19)                           Primary (19)                  VLNT (15), LVB (4)                                           Submental                                          Yes                                                  12 mo                                                    LYMQOL                                                                               Individual patient data not reported
  Asuncion et al.     2018             15                   Not mentioned                                                                          LE (10), UE (4), both LE/UE (1)   Not mentioned                 VLNT                                                         Submental                                          Yes                                                  12 mo                                                    LYMQOL                                                                               Individual pre-operative patient data not reported
  Ciudad et al.       2019             16                   ISL stage III (16)                                                                     UE (6), LE (10)                   Secondary (15), Primary (1)   VLNT (with debulking)                                        Gastroepiploic                                     Yes                                                  12 mo                                                    LYMQOL                                                                               Individual patient data not reported
  Maruccia et al.     2019             39                   Not mentioned                                                                          UE                                Secondary                     VLNT (18 also with axillary scar release and fat grafting)   Groin (20), Gastroepiploic (19)                    Yes                                                  12 mo                                                    LYMQOL                                                                               Individual patient data not reported
  Visconti et al.     2019             10                   ISL 2b (10)                                                                            LE                                Secondary                     VLNT                                                         Supraclavicular                                    Yes                                                  12 mo                                                    LYMQOL                                                                               100%

ISL, international society of lymphology; UE, upper extremity; LE, lower extremity; LVB, lymphovenous bypass; VLNT, vascularized lymph node transplant; mo, months.
